Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 148 participants.

Also called NCT01175473

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 148 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01175473
  • EudraCT 2009-017666-23
Main results
  • Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin Diabetes, obesity & metabolism, 2013-07 DOI, PubMed 23368510, PMC3752965 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01175473. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2010-11 (actual). Results posted on 2016-10-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Lixisenatide (AVE0010)
Intervention (Device)
Pen auto-injector
Intervention (Drug)
Liraglutide
Intervention (Device)
Pre-filled pen injector
Intervention (Drug)
Metformin
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01175473
Content hash
5aa37e629b78e5742d2da495c957a4a40d062da9783beba82c5a735be7f7e263